|
KMID : 0361519930040020169
|
|
Korean Journal of Psychopharmacology
1993 Volume.4 No. 2 p.169 ~ p.176
|
|
|
Efficacy and Tolerability of Remoxipride in the Acute phase of Schizophernia in Korean Patients
|
|
|
|
|
Abstract
|
|
|
Thirty four DSM-III-R acute schizophrenic patients were selected for a non-comparative trial of the antipsychotic agent. remoxipride. After at least 3 days washout. patients received remoxipride for 6 weeks. the initial dose was 75mg bid. this
was
subsequently adjusted according to clinical response. Maximum dose was 6700mg a day. During the last week of treatment the median dosage of remoxipride was 225mg bid (range 150 to 300mg bid). With remoxipride treatment. mean BPRS scores decreased
significantly from 38.5 at baseline to 11 at the last rating (P<0.0001) and CGl illness severity scores were significantly reduced (p<0.0001). Adverse events reported were mostly mild and tolerable by patients. Treatment emergent extrapyramidal
symptoms
were few. No clinically significant changes in clinical chemistry or haematology were detected. Remoxipride was found to be and effective. well tolerated and safe antipsychotic agent for the treatment of acute schizophrenia in Korean patients.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|